Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15

Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA

Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy, or SMA, were presented at the 2018 Annual Cure SMA Conference in Dallas. This hypothesis-generating study met its primary objective to determine potential pharmacodynamic effects of reldesemtiv after multiple oral doses in patients with SMA, and secondary objectives to evaluate the safety, tolerability and pharmacokinetics of reldesemtiv. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study showed dose- and concentration-dependent increases in time to muscle fatigue as measured by changes from baseline in Six Minute Walk Distance, a sub-maximal exercise test of aerobic capacity and endurance, and Maximal Expiratory Pressure, a measure of strength of respiratory muscles, after eight weeks of treatment with reldesemtiv. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight. The study also showed increases versus placebo in MEP. Adverse events were similar between groups receiving reldesemtiv and placebo. The most commonly observed adverse effects were headache, constipation and nausea. Four patients had serious adverse events reported that resulted in early termination of study drug treatment, all considered to be unrelated to reldesemtiv.

CYTK Cytokinetics
$9.95

0.5 (5.29%)

11/22/17
11/22/17
DOWNGRADE
Target $10

Neutral
Cytokinetics downgraded after tirasemtiv discontinuation at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald analyst Mara Goldstein downgraded Cytokinetics to Neutral from Overweight after the VITALITY-ALS trial failed and the company announced the discontinuation of the tirasemtiv program. While she sees opportunity for upside as clinical data emerge on omecamtiv and CK-2127107, she argues that the time to meaningful data and proximity to year-end makes a Neutral rating appropriate. Goldstein lowered her price target on Cytokinetics to $10 from $21.
11/22/17
NEED
11/22/17
DOWNGRADE
Target $12
NEED
Buy
Cytokinetics downgraded to Buy at Needham after failed tirasemtiv Phase 3
As reported earlier, Needham analyst Chad Messer downgraded Cytokinetics to Buy from Strong Buy and cut his price target to $12 from $22 after the company's Phase 3 study of tirasemtiv inamyotrophic lateral sclerosis failed to reach its efficacy endpoints. Messer says the culprit was the high dropout rates due to the tolerability issues of tirasemtiv. The analyst notes that the company will now turn its focus to developing CK-107, which has a superior tolerability profile. Messer adds that the Buy rating still reflects his expectations of potential value creation from CK-107 in FY18.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/19/18
HCWC
01/19/18
NO CHANGE
Target $20
HCWC
Buy
Cytokinetics price target raised to $20 from $17 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $20 after spending time with management. CK-107 could be the molecule that resets the investment thesis in 2018, Pantginis tells investors in a research note. The analyst looks for a "quick turnaround" in 2018 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

15:05
10/16/18
10/16
15:05
10/16/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MAXR

Maxar Technologies

$30.30

0.89 (3.03%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Hot Stocks
Maxar's MDA ships final spacecraft in preparation for RADARSAT mission »

MDA, a Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$144.76

3.64 (2.58%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Options
IBM options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

BA

Boeing

$367.17

8.36 (2.33%)

15:02
10/16/18
10/16
15:02
10/16/18
15:02
Hot Stocks
Boeing sees air cargo traffic doubling in 20 years »

Boeing projects air cargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

CLDR

Cloudera

$15.68

0.44 (2.89%)

15:01
10/16/18
10/16
15:01
10/16/18
15:01
Hot Stocks
Cloudera announces strategic alliance with NEC »

Cloudera announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MNKD

MannKind

$1.90

0.24 (14.46%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Hot Stocks
FDA sends warning letter to MannKind over Affrezza marketing »

In a warning letter sent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.93

1.44 (3.10%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Options
Call spread in Crown Holdings in front of earnings »

Call spread in Crown…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

, JPM

JPMorgan

$108.59

2.25 (2.12%)

14:55
10/16/18
10/16
14:55
10/16/18
14:55
Recommendations
On Deck Capital, JPMorgan analyst commentary  »

Janney Montgomery Scott…

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

JPM

JPMorgan

$108.59

2.25 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 06

    Nov

  • 26

    Feb

OSTK

Overstock.com

$27.11

0.33 (1.23%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Hot Stocks
Overstock.com says Customer Day 'strongest' non-Holiday sale in company history »

Overstock.com reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$60.29

1.36 (2.31%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Options
DowDuPont draws call buyers »

DowDuPont draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$341.60

8.49 (2.55%)

14:49
10/16/18
10/16
14:49
10/16/18
14:49
Options
Netflix options imply 14.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 13

    Nov

14:45
10/16/18
10/16
14:45
10/16/18
14:45
General news
Canada Manufacturing Preview »

Canada Manufacturing…

H

Hyatt

$72.79

1.08 (1.51%)

14:42
10/16/18
10/16
14:42
10/16/18
14:42
Recommendations
Hyatt analyst commentary  »

Hyatt to-be-acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ALLY

Ally Financial

$25.87

-0.22 (-0.84%)

14:40
10/16/18
10/16
14:40
10/16/18
14:40
Options
Ally Financial attracts put buying as shares see relative weakness »

Ally Financial attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CDNS

Cadence Design

$40.13

0.74 (1.88%)

14:34
10/16/18
10/16
14:34
10/16/18
14:34
Hot Stocks
Cadence Design says Verification Suite enabled for HPC server environments »

Cadence Design Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

EEM

iShares MSCI Emerging Markets ETF

$40.79

0.95 (2.38%)

14:30
10/16/18
10/16
14:30
10/16/18
14:30
Options
Aggressive call spread opened in iShares Emerging Markets Fund »

Aggressive call spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$36.25

3.81 (11.74%)

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Conference/Events
Financial Stability Oversight Council to hold a meeting »

The Council will provide…

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

, AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

14:23
10/16/18
10/16
14:23
10/16/18
14:23
Periodicals
Walgreens CEO says buyout of AmerisourceBergen possible, Bloomberg reports »

Walgreens Boots Alliance…

WBA

Walgreens Boots Alliance

$75.55

0.83 (1.11%)

AMZN

Amazon.com

$1,811.22

50.23 (2.85%)

CVS

CVS Health

$73.05

0.01 (0.01%)

AET

Aetna

$199.90

0.88 (0.44%)

ABC

AmerisourceBergen

$92.51

2.93 (3.27%)

RAD

Rite Aid

$1.05

-0.005 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

  • 06

    Nov

RP

RealPage

$58.71

2.33 (4.13%)

14:22
10/16/18
10/16
14:22
10/16/18
14:22
Hot Stocks
RealPage pays $3M to settle FTC charges over tenant screening »

RealPage has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MARA

Marathon Patent Group

$0.62

-0.0034 (-0.55%)

14:18
10/16/18
10/16
14:18
10/16/18
14:18
Hot Stocks
Breaking Hot Stocks news story on Marathon Patent Group »

Merrick D. Okamoto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/16/18
10/16
14:17
10/16/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/16/18
10/16
14:16
10/16/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$220.75

5.47 (2.54%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Goldman Sachs analyst commentary  »

JMP Securities sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 26

    Oct

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

, DG

Dollar General

$110.50

4.08 (3.83%)

14:07
10/16/18
10/16
14:07
10/16/18
14:07
Recommendations
Dollar Tree, Dollar General, Amazon.com analyst commentary  »

Reported Icahn stake in…

DLTR

Dollar Tree

$86.09

5.11 (6.31%)

DG

Dollar General

$110.50

4.08 (3.83%)

AMZN

Amazon.com

$1,808.50

47.51 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 25

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.